Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine

• Published in: Vaccine 2006-04, Vol.24 (15), p.2843-2849
• Main Authors: Hepburn, M.J., Kortepeter, M.G., Pittman, P.R., Boudreau, E.F., Mangiafico, J.A., Buck, P.A., Norris, S.L., Anderson, E.L.
• Format: Article
• Language: English
• Subjects: Adult; Antibodies, Viral - blood; Applied microbiology; Arboviroses; Biological and medical sciences; Booster; Female; Fever; Fundamental and applied biological sciences. Psychology; Human viral diseases; Humans; Immunization, Secondary; Infectious diseases; Male; Medical Laboratory Personnel; Medical research; Medical sciences; Microbiology; Middle Aged; Military Personnel; Neutralization Tests; Neutralizing antibody; Retrospective Studies; Studies; Time Factors; Tropical viral diseases; United States; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Vector-borne diseases; Viral diseases; Yellow fever; Yellow fever vaccine; Yellow Fever Vaccine - administration & dosage; Yellow Fever Vaccine - immunology
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2005.12.055

A retrospective review was conducted of yellow fever vaccination among laboratory workers receiving annual serologic assessment to determine the initial and long-term response after boosting. Patients were divided into three groups based on pre-vaccination serology: Group 1, 1:10; Group 2, 1:20–1:40 and Group 3, >1:40. The percent with ≥four-fold increase in titers after booster vaccination were: 78% (646/829, Group 1), 65% (79/121, Group 2) and 10% (8/79, Group 3) ( p < 0.0001). The median times to titer failure (